Departments of 1 Surgery and 2 Endocrinology and Diabetes and 3 Gustaf V Research Institute, Karolinska Hospital, S-171 76 Stockholm, Sweden; and 4 Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Elective surgery was
performed after overnight fasting, a routine that may affect the
metabolic response to surgery. We investigated the effects of insulin
and glucose infusions before and during surgery on postoperative
substrate utilization and insulin sensitivity. Seven patients were
given insulin and glucose infusions 3 h before and during surgery
(insulin group), and a control group of six patients underwent surgery
after fasting overnight. Insulin sensitivity and glucose kinetics
(D-[6,6-2H2]glucose)
were measured before and immediately after surgery using a
hyperinsulinemic, normoglycemic clamp. Glucose infusion rates and whole
body glucose disposal decreased after surgery in the control group
(40 and
29%, respectively), whereas no significant
change was found in the insulin group (+16 and +25%). Endogenous
glucose production remained unchanged in both groups. Postoperative
changes in cortisol, glucagon, fat oxidation, and free fatty acids were
attenuated in the insulin group (vs. control). We conclude that
perioperative insulin and glucose infusions minimize the endocrine
stress response and normalize postoperative insulin sensitivity and
substrate utilization.
glucose metabolism; glucose-clamp technique; insulin resistance
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
GIVEN THE WIDESPREAD USE of surgical treatment, it is important to minimize the negative side effects of the surgery, such as the catabolic response (22, 57). For about 150 years, elective surgery has been routinely performed after overnight fasting to ensure an empty stomach. Recently, several countries have changed their recommendations for preoperative fasting to allow intake of clear fluids up to 2-3 h before surgery (51). Importantly, the fasting period before surgery is often long enough (10-16 h) to substantially deplete carbohydrate reserves and change the metabolic situation of the patient (48), and clear fluids have minimal effects on metabolism. The rationale for operating on patients in a fasted state instead of a fed state, normally occurring during the day, has not really been questioned.
The effect of changing the metabolic setting from an overnight fasted
to a "fed state" before the trauma (i.e., surgery) on the
subsequent development of the catabolic response has only recently been
tested (38). Thus an overnight treatment with glucose infusions (5 mg · kg1 · min
1)
before surgery substantially reduced the decrease in insulin sensitivity 24 h after uncomplicated abdominal surgery, compared with
the levels in patients undergoing the same operation after overnight
fasting. These findings suggest that fasting before surgery may
contribute to the decline in insulin sensitivity that occurs with
surgery. However, from that previous study (38), it was difficult to
determine whether the large dose of carbohydrates (~300 g) given
overnight or the accompanying elevation of insulin (~4 times above
normal fasting levels, 45 µU/ml) was the key factor in the reported
effects. In addition, a recent study shows that the common
perioperative fluid regimen [2,000-3,000 ml of balanced electrolyte solutions containing a small amount of glucose (2.5%), accompanied by immobilization] has an impact on insulin
sensitivity as early as after 24 h (42). To distinguish these
influences from the outcome parameters, the effects of the treatments
were studied immediately after the completion of surgery.
The aims of the present study were to investigate the effects of exogenous insulin and glucose infusion, begun shortly before surgery and continued throughout the surgery, on body metabolism, insulin sensitivity, and endocrine responses immediately after a medium-sized elective operation. The insulin infusion was gauged to achieve a physiological elevation of insulin, whereas glucose was given to maintain normoglycemia.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Subjects. Thirteen patients scheduled for total hip replacement were studied. We excluded patients >65 yr of age, with a personal or family history of diabetes mellitus or other metabolic diseases and on regular treatment with drugs known to affect glucose metabolism. The patients were randomized to either undergo surgery with (n = 7, insulin group, 2 males) or without (n = 6, control group, 5 males) hyperinsulinemic, normoglycemic clamp (see below). The age of the patients was 56 ± 5 and 59 ± 3 yr (means ± SE), and the body mass index (BMI) was 25.0 ± 1.0 and 26.5 ± 1.0 kg/m2 in the insulin and control groups, respectively. All subjects were informed orally and in writing about the purpose and nature of the study, and their informed consent was obtained before their participation. The protocol was approved by the institutional Ethics Committee.
The fact that the groups were not matched for gender differences is likely to have little influence on the postoperative (postop) change in insulin sensitivity found here (55). To assess the influence of this factor on the present measurements, 16 additional patients undergoing elective hip replacement were studied [age 62 ± 2 yr, BMI 25 ± 1 kg/m2, preoperative (preop) insulin sensitivity 3.65 ± 0.3 mg · kgAnesthetics and perioperative and postop care. In all patients, surgery was commenced between 10:40 AM and 1:40 PM (no difference between groups). The same anesthetic procedures were employed in all patients. Premedication was provided by injection of morphine (Morfin Pharmacia, Pharmacia, Sweden; 5-15 mg im), according to body weight. Spinal anesthesia was induced with bupivacaine (Marcain Spinal, Astra, Södertälje, Sweden; 15-18 mg) immediately before surgery. All patients were fully anesthetized by the spinal anesthesia during the whole study (sensitivity to temperature and pain tested intermittently) (59), and no other anesthetics were used. Sedation was provided on demand with no difference between the groups, by the occasional use of midazolam (Dormicum, Roche, Basel, Switzerland; 1.25-2.5 mg) and/or piperazinylphentiazine (Esucos, UCB, Brussels, Belgium; 5 mg iv). Prophylactic treatment to avoid postop thrombosis was given to all patients using a subcutaneous injection of 5,000 U of anti-Xa (Fragmin, Pharmacia-Upjohn, Stockholm, Sweden) the night before surgery.
Total hip replacement was performed by use of the posterior approach with the patients lying on their side. The duration of surgery and perioperative blood loss was similar in both groups [124 ± 4 vs. 110 ± 6 min and 1,319 ± 165 vs. 1,316 ± 177 ml, P = not significant (NS), insulin and control groups, respectively]. The postop course was uneventful in all patients. The hospital stay was 4.4 ± 0.3 vs. 5.7 ± 0.6 days in insulin and control groups, respectively (P = 0.067).Study design. The study was designed to investigate the effects of exogenous insulin and glucose infusions, given to achieve a physiological elevation of insulin (27) while maintaining normoglycemia before and during surgery, on postop insulin sensitivity, substrate oxidation, and endocrine responses.
On the morning of the surgery, patients in the insulin group were studied after fasting overnight. Insulin infusions were started at 8:00 AM after a basal study period of 30 min (Fig. 1). Insulin (Actrapid, Novo, Copenhagen, Denmark) was infused at a constant rate (0.8 mU · kg
|
Glucose turnover measurements and indirect calorimetry.
Primed (3 mg/kg), continuous (2.4 mg · kg1 · h
1)
infusions of
[6,6-2H2]glucose
(Isotec, Miamisburg, OH) were given for 120 min before the basal period
as well as throughout the hyperinsulinemic, normoglycemic clamp
studies. The
D-[6,6-2H2]glucose
was sterile and nonpyrogenic and proved to be >96% pure by HPLC. The
infusions were performed with a syringe pump (Perfusor-Secura, Braun,
Melsungen, Germany). To minimize changes in plasma
D-[6,6-2H2]glucose
enrichment during the clamp,
D-[6,6-2H2]glucose
was added to the glucose infusate (19, 20). Glucose disappearance was
calculated using a modified Steele equation, taking into account the
varying tracer infusion rates (13, 19, 20). The glucose volume of
distribution was estimated to be 250 ml/kg and the pool correction
factor 0.65. Endogenous glucose production (EGP) was calculated by
subtracting the glucose infusion rate from the tracer-determined rate
of appearance (19, 20).
Sampling and analysis.
All blood was sampled in a standardized way in conformity with the
study protocol. Arterialized blood samples were collected from a heated
hand vein (10). Blood glucose was sampled at least every 10 min during
the study and was analyzed immediately after collection by use of the
glucose oxidase method (Yellow Springs Instruments, Yellow Springs, OH)
(31). Plasma samples for the determination of isotope enrichment levels
were collected before the infusion and every 10 min during the study
periods. The glucose infusion rate (GIR) during each 10-min interval
was recorded repeatedly, and the calculations were performed during
each study period as indicated in the study design (see above). EGP and
whole body glucose disposal (WGD) were calculated from the GIR and
enrichment levels.
Trimethylsilyl-O-methyloxime
derivative of plasma glucose was analyzed in a gas chromatography-mass
spectrometer to measure D-[6,62H2]glucose
isotopic enrichment in the tracer, glucose infusates and plasma samples
(34). Serum insulin was sampled every 30 min during the study and
analyzed by RIA using an antibody developed in our laboratory (26). The
following substrates and hormones were measured once at the end of four
of the study periods (basal, preop, late op, and postop) as well as 10 min after the initiation of surgery (early op). Plasma lactate was
measured by use of the lactate oxidase method. Serum C-peptide (Novo
Research, Bagsværd, Denmark), serum cortisol (60), serum insulin-like
growth factor I (IGF-I) (2), serum IGF-binding protein-1 (IGFBP-1)
(43), and plasma glucagon (Euro-Diagnostica, Malmö, Sweden) (17) were analyzed by using RIA methods. Free fatty acids (FFA) were determined after lipid extraction of plasma (15) according to Ho (30).
Serum samples were permitted to clot, whereas plasma samples were
immediately centrifuged at 4 and 3,000 rpm for 10 min and stored at
20°C for later batch analyses. Urinary urea was analyzed by
an AutoAnalyzer (Ektachem 700 XR, Eastman Kodak, Rochester, NY).
Control study in healthy subjects not undergoing surgery.
To evaluate the effect of the prolonged hyperinsulinemic, normoglycemic
clamp in the insulin group, a separate group of healthy subjects
(n = 5, 4 males, age 38 ± 7 yr,
BMI 24 ± 1 kg/m2) was
studied after overnight fasting, during an 8-h hyperinsulinemic (0.8 mU · kg1 · min
1),
normoglycemic (4.5 mM) clamp. Substrate oxidation was measured by
indirect calorimetry (see above), and levels of glucose, FFA, insulin,
glucagon, cortisol, IGF-I, and IGFBP-1 were analyzed. The relative
change in these parameters during the 8th h of clamp (corresponding to
postop clamp in insulin group) was compared with levels found during
the 2nd h of clamp (corresponding to preop clamp in insulin group).
Statistics. All values are given as individual values or means ± SE. Samples taken repeatedly during the five study periods (i.e., glucose, insulin, GIR, EGP, and WGD) are given as mean values during each study period (see above). Statistical significance was accepted at P < 0.05 by Wilcoxon's signed-rank test and the Mann-Whitney U-test for paired and unpaired data, respectively. A two-way ANOVA for repeated measures was used to assess changes related to the three study periods during and after surgery (early op, late op, and postop clamp). Correlations were tested by multiple or simple regression.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Blood glucose and plasma lactate. Fasting glucose levels were not significantly different between the insulin and control groups at any point in time during the study (Table 1). During preop and postop clamps, the mean intraindividual coefficient of variation (CV) for glucose was 4.6% in the control group and 6.2% in the insulin group. Plasma lactate (Table 1) levels were lower (P < 0.05 vs. insulin) in the control group during the preop clamp as well as during surgery. However, plasma lactate levels did not change significantly after surgery in any of the groups compared with preop levels. When the results during and after surgery were analyzed, no difference was found regarding blood glucose levels, whereas significantly lower lactate levels were found in the control group (P < 0.05 vs. insulin, ANOVA).
|
FFA levels. Plasma FFA levels did not differ significantly between the groups before surgery. During surgery as well as during the postop clamp, levels of FFA were higher in the control group than in the insulin group (P < 0.0001, ANOVA).
Insulin and C-peptide levels. Serum insulin (Table 1) in the control group was unchanged compared with basal levels and was lower than in the insulin group (P < 0.01) during surgery. Insulin levels during preop and postop clamps were similar in the groups (Table 1). C-peptide levels (Table 1) were similar in the groups before surgery. During surgery (i.e., early op), higher levels were found in the control group (P < 0.05). Levels of C-peptide did not change at the postop clamp compared with the preop clamp in any group.
IGF-I and IGFBP-1. Serum IGF-I (Table 1) did not differ between the groups at any time point. During the postop clamp, IGF-I decreased (P < 0.05) in both groups compared with the preop clamp. Serum IGFBP-1 did not differ between the groups before surgery. During surgery, significantly higher levels were found in the control group than in the insulin group. During the postop clamp, IGFBP-1 decreased in the insulin group (P < 0.05), whereas increased levels (P < 0.05) were found in the control group compared with the preop clamp (Fig. 2). Levels of IGFBP-1 were higher (P < 0.05) in the control group than in the insulin group at the postop clamp. An analysis of changes during and after surgery showed that levels of IGF-I fell significantly in both groups during this period (P < 0.01, ANOVA), the fall being greater in the controls than in the insulin group (P < 0.05). In addition, levels of IGFBP-1 were lower in the insulin group than in the controls during and after surgery (P < 0.05, ANOVA).
|
Cortisol and glucagon levels. Plasma glucagon levels were lower (P < 0.01) in the control group during the preop clamp. In both groups, glucagon levels decreased (P < 0.05) after surgery (Table 1). Serum cortisol levels did not differ significantly between the groups at any time. However, during the postop clamp, cortisol levels decreased by 65% in the insulin group (P < 0.05 vs. preop clamp), whereas no significant difference was found in the control group (P = 0.1). The relative changes in levels of cortisol and glucagon at the postop clamp (vs. preop clamp) were significantly different in the control and insulin groups (Fig. 2). During and after surgery, glucagon decreased (P < 0.01, ANOVA), whereas no difference was found between the groups. Furthermore, the change in the cortisol levels during this period of time (P < 0.01, ANOVA) was different in the two groups (P < 0.0001, ANOVA).
Glucose kinetics.
Plasma isotope enrichment levels (specific activities) were stable
during all measurements, with mean intraindividual CVs of 4.2 ± 0.5 and 5.2 ± 0.4% in the control and insulin groups, respectively.
Mean levels of plasma enrichments were 1.8 ± 0.0% molar excess.
Basal levels of EGP and WGD were higher
(P < 0.05) in the control group than
in the insulin group. During preop clamps, GIRs required to maintain
normoglycemia and WGD (Table 2) did not
differ significantly between the two groups. GIRs were lower in the
control group during the postop clamp than during the preop clamp
(40 ± 5%, P < 0.05),
whereas no significant change was found in the insulin group (+16 ± 20%, P = NS). In addition, WGD was
lower in the control group during the postop clamp than during the
preop clamp (
29 ± 6%, P < 0.05), whereas no significant change was found in the insulin group
(+25 ± 11%, P = NS).
During the postop clamp, levels of GIR
(P = 0.01) and WGD
(P < 0.05) were lower in the control
group than in the insulin group. Furthermore, the relative change in
GIR (P = 0.01, Fig.
3) and WGD
(P < 0.005) during the postop clamp,
compared with the preop clamp, differed between the insulin and control
groups. EGP (Table 2) was almost totally suppressed during both preop
and postop clamps in both groups, although a small but significant
increase in EGP was noted during the postop clamp compared with the
preop clamp (P < 0.05) in the
insulin group. During and after surgery, levels of EGP were higher
(P < 0.0001, ANOVA) but WGD was
lower (P < 0.05, ANOVA) in the
controls than in the insulin-treated patients.
|
|
Indirect calorimetry. Substrate oxidation rates (Table 2) did not differ between the groups in the preop situation. During surgery, fat oxidation was higher (P < 0.05) and glucose oxidation rates were lower (P < 0.05) in the control group than in the insulin group. No significant differences in substrate oxidation rates were found during the postop clamp compared with the preop clamp in any group. However, higher fat oxidation rates (P < 0.05) were found in the control group compared with the insulin group during the postop clamp.
Glucose utilization (percent oxidized of WGD) did not differ between the groups at any time. No significant change was found in glucose utilization after surgery in any group. Resting EE in the basal state was higher in the control group than in the insulin group before surgery. EE did not change significantly in the insulin group after surgery, whereas a significant decrease (P < 0.05) was found in the control group. During and after surgery, levels of glucose oxidation were lower (P < 0.01, ANOVA) and fat oxidation was higher (P < 0.001, ANOVA) in the controls than in the insulin-treated patients. Furthermore, glucose utilization increased similarly in the two groups (P < 0.05, ANOVA) but remained higher in the control group (P < 0.01, ANOVA) than in the insulin group during and after surgery. EE increased (P < 0.01, ANOVA) during this period of time but did not differ between the groups.Healthy subjects not undergoing surgery.
The mean blood glucose levels during clamps were 4.5 ± 0.0 mM with
a mean intraindividual CV of glucose of 7.2 ± 1.0%. Mean serum
levels of insulin during the two clamp periods (59 ± 2 and 57 ± 2 µU/ml) did not differ from those found in the insulin group. The
relative change in the GIR during the 8th h of clamp (corresponding to
postop clamp in insulin group) compared with the 2nd h of clamp (corresponding to preop clamp in insulin group) was similar to what was
found in the insulin group (+16 ± 10%,
P > 0.05, Fig. 3). The same trends
were found regarding the change in fat (4 ± 12%, Fig. 3) and
glucose (0 ± 4%, Fig. 3) oxidation rates, levels of FFA (29 ± 13%), cortisol (
16 ± 37%, Fig. 2), and IGFBP-1 (
29 ± 13%, Fig. 2), whereas levels of glucagon (
13 ± 2%, Fig. 2) and IGF-I (
3 ± 3%) were less reduced
(P < 0.05) in the subjects not
undergoing surgery than in the insulin group.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
This study demonstrates for the first time that it is possible to maintain normal insulin sensitivity and substrate oxidation after a medium-sized operation by administering insulin and glucose infusions before and during surgery. Using this method, we observed a reduction in glucagon and cortisol levels but a normalization of the bioavailibility of IGF-I, as measured by levels of IGFBP-1, in the immediate postop state. These changes were similar to what was found in healthy subjects during an equivalent period of insulin and glucose administration without the corresponding surgery. In contrast, patients subjected to the same surgical procedure after fasting overnight displayed the expected decrease in insulin sensitivity (7, 56-58) and reduction in IGF-I bioavailibility (47) immediately after surgery.
The patients in this study were randomly assigned to receive one of the two treatments. As the randomization came out, there was an uneven gender distribution between the two groups. This could possibly be a factor affecting the outcome. However, when the issue of the effect of patient parameters on postop insulin sensitivity in a larger group of patients studied immediately after elective hip replacement was addressed, it could be seen that gender, age, BMI, and preop insulin sensitivity are all variables that do not affect the development of postop insulin resistance (55).
Another potential factor that may influence the comparison between the two groups is that the preop determination was made on the morning of surgery in the insulin group, whereas the corresponding determination was made 1 wk before surgery in the control group. The possibility of an effect from differences in anxiety, physical activity, dietary intake, or fatigue between the two groups cannot be ruled out. However, several factors suggest that the potential effect of these differences is not likely to be of great importance. In our own experience, we have found that repeated determinations of insulin sensitivity in the same individuals are very constant (CV ~5-8%; M. Soop, J. Nygren, A. Thorell, and O. Ljungqvist, unpublished observations), despite our impression that most subjects are more anxious during their first clamp study than during any subsequent study. Also, there were no major differences in the basal measurements between the two groups to indicate marked differences at the time of the determinations. Although any potential effect of the above factors cannot be ruled out, it is reasonable to assume that they had little impact on the outcome of the present data.
Although treatments of various catabolic conditions with anabolic hormones, such as growth hormone and IGF-I, have been in the spotlight during the last few years (64), less attention has been paid to insulin. However, some early studies have shown reduced nitrogen losses after treatment with insulin in catabolic traumatized patients (9, 29, 63). A recent study demonstrates a significant anabolic effect on protein metabolism in catabolic burned patients by use of pharmacological infusions of insulin and glucose over several days (50). Yet another study shows that the decreased glucose uptake in the postop state can be overcome by insulin treatment (6), and this treatment also normalized substrate oxidation and improved nitrogen balance. Even though benefits of insulin administration have been demonstrated in catabolic patients, only an attenuation of the catabolic response has been reported to be achieved even when large doses of insulin were used (50, 63). Such large doses of insulin require intensive and constant attention to avoid severe hypoglycemia, which makes this approach difficult in clinical practice.
A different approach to postop catabolism was employed in the present study. The hypothesis was that the preop overnight fast represents an additional stress which augments the development of postop catabolism. Therefore, the metabolic state was reversed to a fed state by an exogenous insulin infusion before the start of surgery. Starting the treatment before starting the surgery was intentional, since several animal studies have shown that coping with stress is much improved if the animals enter the trauma in a fed rather than fasted state (16, 35-37).
Postop insulin sensitivity was determined immediately after surgery to minimize the effect of hypocaloric nutrition on insulin sensitivity (42). The insulin infusion rate was chosen to obtain physiological levels of insulin in the range found after a standard meal (27). At this rate of infusion, EGP was, as expected, almost completely suppressed during both the preop and postop clamps in both groups (32, 42). The prolonged insulin infusion in only one of the two groups could possibly influence the comparison between the two groups in the postop situation, since prolonged insulin infusions have been suggested to increase GIR (14). In the present study, we found a trend toward an increase in GIR during the 8-h clamp in the subjects not undergoing surgery. A very similar trend was also seen in the insulin group. This shows that the change in whole body insulin sensitivity (i.e., GIR) in the insulin group is what is to be expected in healthy subjects given this insulin and glucose treatment.
From this study, although conducted with a limited number of patients,
it is clear that it is possible to perform surgery without any
immediate stress response provided that the patient undergoes surgery
during insulinization. The clinical relevance of these findings is
supported by a study by Crowe et al. (11), in which they reported
decreased urinary urea and 3-methylhistidine excretion in
patients given high-dose glucose infusions (5 mg · kg1 · min
1)
after abdominal surgery. Furthermore, patients given glucose infusions
before surgery displayed a decrease in urinary urea excretion during
the first 24 h after surgery compared with patients in whom glucose
infusions were started after surgery (11), suggesting that the preop
treatment may be more effective. A study in a larger number of patients
would be required to determine whether our present findings may lead to
shorter hospital stays or other clinical end points. However, it is
interesting to note that the hospital stay in the insulin group tended
to be shorter (4 vs. 6 days, P = 0.067) than in the control group.
Several factors known to trigger the metabolic response after trauma were affected by insulin and glucose infusions. Thus the stress hormone response was attenuated, the level of IGFBP-1 was decreased, and the level of FFA was maintained. All of this could help explain why the postop insulin sensitivity and substrate handling were virtually unaffected by surgery in this group.
The cortisol reduction found after surgery in the insulin group resembles the normal diurnal pattern. This was in contrast to that found in the control group (62). The differences found in glucocorticoid responses in the present study paralleled those in earlier animal studies (35). Although rats fasted 24 h before hemorrhagic stress showed a fourfold elevation in corticosterone during hemorrhage, this response was completely abolished in rats fed until the onset of stress. High cortisol levels are known to increase protein wasting by increasing protein breakdown and amino acid oxidation (3). Although less pronounced than the cortisol response, the glucagon levels were lower in the insulin group. Glucagon is a potent stimulator of gluconeogenesis, but its role in peripheral tissues is still a matter of controversy (40). Nevertheless, elevations of both these hormones are known to cause insulin resistance (1, 25, 39, 61), and the patterns presently found may contribute to the differences in postop metabolism seen in the two treatment groups.
Although the main focus in stress was on the catabolic hormones for a long time, the role of the anabolic hormones in trauma metabolism is receiving more and more attention. IGF-I levels have been shown to be markedly reduced after burn trauma (41), in critical illness (46), and after major surgical procedures (12). In the present study, IGF-I levels decreased in the control group in response to surgery, whereas levels of IGFBP-1 increased. Levels of IGFBP-1 are important, since this binding protein must be considered when assessing the biological significance of serum levels of IGF-I (28). IGFBP-1 has been shown to decrease IGF-I activity and receptor binding in different cell lines (45, 49). In addition, IGFBP-1 has been shown to be inversely proportional to levels of free IGF-I in obese insulin-resistant patients (23) as well as to IGF-I activity, as measured by bioassays in diabetic patients (54). In contrast to the finding in the control group, levels of IGFBP-1 decreased after surgery in the insulin group. This was probably mediated by insulin, since IGFBP-1 levels are inversely regulated by insulin (8). Even though IGF-I activity was not measured directly, changes in levels of IGFBP-1 indicate that the insulin and glucose infusion resulted in maintaining or even improving the bioavailibility of IGF-I. In contrast, the increased levels of IGFBP-1 found in the group undergoing surgery after the traditional fasting indicate a reduced bioavailibility and action of IGF-I after surgery. Again, this difference could contribute to the overall metabolic situation after surgery.
Increased availability of lipids after trauma have been suggested to induce insulin resistance through the glucose-fatty acid cycle (44). In the present study, FFA levels and fat oxidation rates were higher after surgery in the control group than in the insulin group. Previous studies on healthy subjects, as well as on non-insulin-dependent diabetes mellitus patients, demonstrated that increased availability of lipids decreases insulin sensitivity and glucose oxidation even in the presence of simultaneous infusions of insulin (5, 18). However, if insulin was infused for 2 h before the start of the infusion of lipids, no changes in GIR or substrate oxidation rates were seen during clamps (5), suggesting that the adjustment of metabolism (i.e., with or without insulin) before the initiation of lipid infusion may be critical for FFA to exert this effect. It is possible that a parallel mechanism could contribute to the presently found differences between the groups.
Another difference between the two treatment groups was the finding of lower lactate levels in the control group during surgery. This was associated with a higher EGP in the controls. These findings may be due to a higher consumption of lactate for gluconeogenesis. Also, the higher lactate levels in the insulin group may be a result of the greater disposal of glucose resulting in a higher production of lactate. This, coupled with a suppressed EGP, may account for the difference between the groups.
Previous studies indicate that the peripheral insulin resistance that develops after trauma may be due to a postreceptor defect (4). Thus changes in the glucose transport system have been suggested to be involved in the development of peripheral insulin resistance (24, 33). The current reduction of glucose disposal in the control group is consistent with a transport defect, since the relative part of glucose disposal being oxidized was unchanged after surgery. If anything, the trend of the data suggests that the decreased insulin sensitivity in the control group after surgery was accompanied primarily by a reduction in glucose storage while glucose oxidation was better preserved.
From the present investigation, we conclude that it is possible to keep important aspects of metabolism completely normal after surgery by changing the metabolic profile with insulin and glucose infusions started before surgery and maintained during surgery. Performing surgery with the patient in the fed state, in this case by providing insulin and glucose, instead of the traditional fasted state, makes possible a completely different starting point for postop nutrition and recovery.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank nurses Lotta Hylén and Caisa Almström for excellent technical assistance with the clamps, Peter Berg and Berit Rydlander for skillful assistance with the sample analyses, and the staff at the Department of Orthopedic Surgery for good cooperation.
![]() |
FOOTNOTES |
---|
This work was supported by grants from the Karolinska Institute, the Swedish Medical Research Council (09101, 18406, and 4224), the Swedish Diabetes Association, Fredrik and Ingrid Thüring's Foundation, the Swedish Society of Medicine, Torsten and Ragnar Söderberg's Foundation, National Institute of Health grants (RO1-DK-41973 and RR-00585), and Nutricia Corporate Research, Zoetermeer, The Netherlands.
Preliminary data from this study were reported at the 18th Congress of the European Society of Enteral and Parenteral Nutrition in Geneva, Sept. 8-11, 1996.
Present address of O. Ljungqvist and A. Thorell: Huddinge Univ. Hospital, S-141 86 Huddinge, Sweden.
Address reprint requests to O. Ljungqvist.
Received 4 June 1997; accepted in final form 10 March 1998.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Alberti, K. G. M. M.,
G. F. Batstone,
K. J. Foster,
and
D. G. Johnston.
Relative role of various hormones in mediating the metabolic response to injury.
JPEN J. Parenter. Enteral Nutr.
4:
141-146,
1980[Medline].
2.
Bang, P.,
U. Eriksson,
V. Sara,
I. L. Wivall,
and
K. Hall.
Comparison of acid gel filtration prior to IGF-1 and IGF-2 radioimmunoassay; improvement by the use of truncated IGF-1 as radioligand in the IGF-1 radioimmunoassay.
Acta Endocrinol.
124:
620-629,
1991[Medline].
3.
Beaufrere, B.,
F. F. Horber,
W. F. Schwenk,
H. M. Marsh,
D. Matthews,
J. E. Gerich,
and
M. W. Haymond.
Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans.
Am. J. Physiol.
257 (Endocrinol. Metab. 20):
E712-E721,
1989
4.
Black, P. R.,
D. C. Brooks,
P. Q. Bessey,
R. R. Wolfe,
and
D. W. Wilmore.
Mechanisms of insulin resistance following injury.
Ann. Surg.
196:
420-435,
1982[Medline].
5.
Bonadonna, R. C.,
K. Zych,
C. Boni,
E. Ferrannini,
and
R. A. DeFronzo.
Time dependence of the interaction between lipid and glucose in humans.
Am. J. Physiol.
257 (Endocrinol. Metab. 20):
E49-E56,
1989
6.
Brandi, L. S.,
M. Frediani,
M. Oleggini,
F. Mosca,
M. Cerri,
C. Boni,
N. Pecori,
G. Buzzigoli,
and
E. Ferrannini.
Insulin resistance after surgery: normalisation by insulin treatment.
Clin. Sci. (Lond.)
79:
443-450,
1990[Medline].
7.
Brandi, L.,
D. Santoro,
A. Natali,
F. Almonte,
S. Baldi,
S. Frascerra,
and
E. Ferrannini.
Insulin resistance of stress: sites and mechanisms.
Clin. Sci. (Lond.)
85:
525-535,
1993[Medline].
8.
Brismar, K.,
E. Fernqvist-Forbes,
J. Wahren,
and
K. Hall.
Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes.
J. Clin. Endocrinol. Metab.
79:
872-878,
1994[Abstract].
9.
Brooks, D.,
P. Bessey,
and
P. Black.
Insulin stimulates branched chain amino acid uptake and diminishes nitrogen flux from skeletal muscle of injured patients.
J. Surg. Res.
40:
395-405,
1986[Medline].
10.
Copeland, K.,
F. Kenney,
and
K. Nair.
Heated dorsal hand vein sampling for metabolic studies: a reappraisal.
Am. J. Physiol.
263 (Endocrinol. Metab. 26):
E1010-E1014,
1992
11.
Crowe, P.,
A. Dennison,
and
G. Royle.
The effect of preoperative glucose loading on postoperative nitrogen metabolism.
Br. J. Surg.
71:
635-637,
1984[Medline].
12.
Davies, S. C.,
J. A. H. Wass,
R. J. M. Ross,
A. M. Cotterhill,
C. R. Buchanan,
V. J. Coulson,
and
J. M. P. Holly.
The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness.
J. Endocrinol.
130:
469-473,
1991[Abstract].
13.
DeBodo, R.,
R. Steele,
N. Altszuler,
A. Dunn,
and
J. Bishop.
On the hormonal regulation of carbohydrate and lipid metabolism.
Recent Prog. Horm. Res.
19:
445-488,
1963.
14.
Doberne, L.,
M. Greenfield,
B. Schulz,
and
G. Reaven.
Enhanced glucose utilization during prolonged glucose clamp studies.
Diabetes
30:
829-835,
1981[Medline].
15.
Dole, V.
A relation between non-esterified fatty acids in plasma and the metabolism of glucose.
J. Clin. Invest.
35:
150-154,
1956.
16.
Eshali, A. H.,
P. O. Boija,
O. Ljungqvist,
C. Rubio,
and
J. Ware.
Twenty-four-hour food deprivation increases endotoxin lethality in the rat.
Eur. J. Surg.
157:
85-89,
1991.
17.
Faloona, G. R.,
and
R. H. Unger.
Glucagon radioimmunoassay technique.
In: Methods of Hormone Radioimmunoassay, edited by B. M. Jaffe,
and H. E. Behrman. New York: Academic, 1974, p. 317-330.
18.
Ferrannini, E.,
E. Barrett,
S. Bevilacqua,
and
R. DeFronzo.
Effect of fatty acids on glucose production and utilization in man.
J. Clin. Invest.
72:
1737-1747,
1983[Medline].
19.
Finegood, D.,
R. Bergman,
and
M. Vranic.
Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps.
Diabetes
36:
914-924,
1987[Abstract].
20.
Finegood, D.,
R. Bergman,
and
M. Vranic.
Modeling error and apparent isotope discrimination confound estimation of endogenous glucose production during euglycemic glucose clamps.
Diabetes
37:
1025-1034,
1988[Abstract].
21.
Frayn, K. N.
Calculation of substrate oxidation rates in vivo from gaseous exchange.
J. Appl. Physiol.
55:
628-634,
1983
22.
Frayn, K. N.
Hormonal control of metabolism in trauma and sepsis.
Clin. Endocrinol.
24:
577-599,
1986[Medline].
23.
Frystyk, J.,
E. Vestbo,
C. Skjaerbaek,
C. E. Mogensen,
and
H. Orskov.
Free insulin-like growth factors in human obesity.
Metabolism
44:
37-44,
1995[Medline].
24.
Garvey, T.
Glucose transport and NIDDM.
Diabetes Care
15:
396-417,
1992[Abstract].
25.
Gelfand, R. A.,
D. E. Matthews,
D. M. Bier,
and
R. S. Sherwin.
Role of counterregulatory hormones in the catabolic response to stress.
J. Clin. Invest.
74:
2238-2248,
1984[Medline].
26.
Grill, V.,
J. Pigon,
S. Hartling,
C. Binder,
and
S. Efendic.
Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high responders.
Metabolism
39:
251-258,
1990[Medline].
27.
Gutniak, M.,
V. Grill,
and
S. Efendic.
Effect of composition of mixed meals, low versus high-carbohydrate content, on insulin, glucagon and somatostatin release in healthy humans and in patients with NIDDM.
Diabetes Care
9:
244-249,
1986[Abstract].
28.
Hall, K.,
K. Brismar,
F. Grissom,
B. Lindgren,
and
G. Povoa.
IGFBP-1. Production and control mechanisms.
Acta Endocrinol.
124:
48-54,
1991[Medline].
29.
Hinton, P.,
S. Littlejohn,
S. P. Allison,
and
J. Lloyd.
Insulin and glucose to reduce catabolic response to injury in burned patients.
Lancet
17:
767-769,
1971.
30.
Ho, R. J.
Radiochemical assay of long chain fatty acids using 63Ni as tracer.
Anal. Biochem.
36:
105-113,
1970[Medline].
31.
Hugget, A. S.,
and
D. A. Nixon.
Use of glucose peroxidase and o-dianisidin in determinations of blood and urinary glucose.
Lancet
2:
368-370,
1957.
32.
Katz, H.,
P. Butler,
M. Homan,
A. Zerman,
A. Caumo,
C. Cobelli,
and
R. Rizza.
Hepatic and extrahepatic insulin action in humans: measurement in the absence of non-steady-state error.
Am. J. Physiol.
264 (Endocrinol. Metab. 27):
E561-E566,
1993
33.
Klip, A.,
and
M. Pâquet.
Glucose transport and glucose transporters in muscle and their metabolic regulation.
Diabetes Care
13:
228-243,
1990[Abstract].
34.
Kory, D.,
and
U. Keller.
Trimethylsilyl-O-methyloxime derivatives for the measurement of [6,6-2H2]-D-glucose-enriched plasma samples by GCMS.
J. Chromatogr.
572:
300-306,
1991.
35.
Ljungqvist, O.,
P. O. Boija,
H. Eshali,
M. Larsson,
and
J. Ware.
Food deprivation alters glycogen metabolism and endocrine responses to hemorrhage.
Am. J. Physiol.
259 (Endocrinol. Metab. 22):
E692-E698,
1990[Abstract].
36.
Ljungqvist, O.,
S. Efendic,
P. Eneroth,
B. Hamberger,
G. Nylander,
and
J. Ware.
Nutritional status and endocrine response to hemorrhage.
Can. J. Physiol. Pharmacol.
64:
1185-1188,
1986[Medline].
37.
Ljungqvist, O.,
E. Jansson,
and
J. Ware.
Effect of food deprivation on survival after hemorrhage in the rat.
Circ. Shock
22:
251-260,
1987[Medline].
38.
Ljungqvist, O.,
A. Thorell,
M. Gutniak,
T. Häggmark,
and
S. Efendic.
Glucose infusion instead of preoperative fasting reduces postoperative insulin resistance.
J. Am. Coll. Surg.
178:
329-336,
1994[Medline].
39.
Marliss, E. B.,
T. T. Aoki,
R. H. Unger,
J. S. Soeldner,
and
G. F. Cahill.
Glucagon levels and metabolic effects in fasting man.
J. Clin. Invest.
49:
2256-2270,
1970[Medline].
40.
Miles, J.,
and
M. Jensen.
Does glucagon regulate adipose tissue lipolysis?
J. Clin. Endocrinol. Metab.
77:
5A-5B,
1993[Medline].
41.
Nygren, J.,
M. Sammann,
M. Malm,
S. Efendic,
K. Hall,
K. Brismar,
and
O. Ljungqvist.
Disturbed anabolic hormonal patterns in burned patients: the relation to glucagon.
Clin. Endocrinol.
43:
491-500,
1995[Medline].
42.
Nygren, J.,
A. Thorell,
F. Karpe,
S. Efendic,
K. Nair,
and
O. Ljungqvist.
The site of insulin resistance after surgery, the contribution of bed rest and hypocaloric nutrition.
Clin. Sci. (Lond.)
93:
137-147,
1997[Medline].
43.
Povoa, G.,
A. Roovete,
and
K. Hall.
Cross reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid.
Acta Endocrinol.
107:
563-570,
1984[Medline].
44.
Randle, P. J.,
A. L. Kerbey,
and
J. Espinal.
Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones.
Diabetes Metab. Rev.
4:
623-638,
1988[Medline].
45.
Ritvos, O.,
T. Ranta,
J. Jalkanen,
A.-M. Suikkari,
R. Voutilainen,
H. Bohn,
and
E.-M. Rutanen.
Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-1 in cultured choriocarcinoma cells.
J. Clin. Endocrinol. Metab.
122:
2150-2157,
1988.
46.
Ross, R.,
J. Miell,
E. Freeman,
J. Jones,
D. Matthews,
M. Preece,
and
C. Buchanan.
Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-1.
Clin. Endocrinol.
35:
47-54,
1991[Medline].
47.
Ross, R. J. M.,
J. P. Miell,
J. M. P. Holly,
H. Maheshwari,
M. Norman,
A. F. Abdulla,
and
C. R. Buchanan.
Levels of GH binding activity, IGFBP-1, insulin, blood glucose and cortisol in intensive care patients.
Clin. Endocrinol.
35:
361-367,
1991[Medline].
48.
Rothman, D.,
I. Magnusson,
D. L. Katz,
R. Shulman,
and
G. Shulman.
Quantification of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C-NMR.
Science
254:
573-576,
1991[Medline].
49.
Rutanen, E.-M.,
F. Pekonen,
and
T. Mäkinen.
Soluble 34 K binding protein inhibits the binding of insulin-like growth factor 1 to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action.
J. Clin. Endocrinol. Metab.
66:
173-180,
1988[Abstract].
50.
Sakurai, Y.,
A. Aarsland,
D. N. Herndon,
D. L. Chinkes,
E. Pierre,
T. T. Nguyen,
B. W. Patterson,
and
R. R. Wolfe.
Stimulation of muscle protein synthesis by long-term insulin infusion in severely burned patients.
Ann. Surg.
222:
283-297,
1995[Medline].
51.
Splinter, W. M.,
and
J. D. Scaefer.
Ingestion of clear fluids is safe for adolescents up to 3 h before anaesthesia.
Br. J. Anaesth.
66:
48-52,
1991[Abstract].
52.
Takala, J.,
O. Keinänen,
P. Väisänen,
and
A. Kaari.
Measurement of gas exchange in intensive care: laboratory and clinical validation of a new device.
Crit. Care Med.
17:
1041-1047,
1989[Medline].
53.
Tappy, L.,
O. E. Owen,
and
G. Boden.
Effect of hyperinsulinemia on urea pool size and substrate oxidation rates.
Diabetes
37:
1212-1216,
1988[Abstract].
54.
Taylor, A. M.,
D. B. Dunger,
M. A. Preece,
J. M. P. Holly,
C. P. Smith,
J. A. H. Wass,
S. Patel,
and
V. E. Tate.
The growth hormone-independent insulin-like growth factor-1 binding protein UP-28 is associated with serum insulin-like growth factor-1 inhibitory bioactivity in adolescent insulin-dependent diabetes.
Clin. Endocrinol.
32:
229-239,
1990[Medline].
55.
Thorell, A.
Insulin Resistance After Elective Surgery and the Effect of Preoperative Glucose Infusion. Stockholm, Sweden: Karolinska Hospital and Institute, 1993.
56.
Thorell, A.,
S. Efendic,
M. Gutniak,
T. Häggmark,
and
O. Ljungqvist.
Development of postoperative insulin resistance is associated with the magnitude of operation.
Eur. J. Surg.
159:
593-599,
1993[Medline].
57.
Thorell, A.,
S. Efendic,
M. Gutniak,
T. Häggmark,
and
O. Ljungqvist.
Insulin resistance after abdominal surgery.
Br. J. Surg.
81:
59-63,
1994[Medline].
58.
Thorell, A.,
J. Nygren,
P. Essén,
M. Gutniak,
A. Loftenius,
B. Andersson,
and
O. Ljungqvist.
The metabolic response to cholecystectomy: insulin resistance after open compared to laparoscopic operation.
Eur. J. Surg.
162:
187-191,
1996[Medline].
59.
Uchida, I.,
T. Asoh,
C. Shirasaka,
and
H. Tsuji.
Effect of epidural analgesia on postoperative insulin resistance as evaluated by insulin clamp technique.
Br. J. Surg.
75:
557-562,
1988[Medline].
60.
Vecsei, P.
Corticosteroids; cortisol, cortisone, corticosterone, compound S, and their metabolites.
In: Methods of Hormone Radioimmunoassay, edited by B. M. Jaffe,
and H. R. Behrman. New York: Academic, 1979, p. 767-796.
61.
Wajngot, A.,
A. Giacca,
V. Grill,
M. Vranic,
and
S. Efendic.
The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders.
Proc. Natl. Acad. Sci. USA
89:
6035-6039,
1992[Abstract].
62.
Weissman, C.
The metabolic response to stress: an overview and update.
Anesthesiology
73:
308-327,
1990[Medline].
63.
Woolfson, A. M. J.,
R. V. Heatley,
and
S. P. Allison.
Insulin to inhibit protein catabolism after injury.
N. Engl. J. Med.
300:
14-17,
1979[Abstract].
64.
Ziegler, T.,
C. Gatzen,
and
D. Wilmore.
Strategies for attenuating protein-catabolic responses in the critically ill.
Annu. Rev. Med.
45:
459-480,
1994[Medline].